MANGOCEUTICALS, INC. (MGRX): Submission of Matters to a Vote of Security Holders
MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 3.03. Material Modification to Rights of Security Holders. As described in Item 5.03 , which is incorporated by reference into this Item 3.03 , Mangoceuticals, Inc. (the “ Company ”) amended its Series B and Series C preferred stock designations effective November 9, 2026, a
How this was made
The 30-second read
Why it matters
The corporate action changes the capital hierarchy, introducing senior dividend and liquidation preferences that could affect common shareholders.
Market read
A micro‑cap filing with limited market impact; relevance mainly for existing shareholders and potential investors.
What to watch
Potential conversion rights after three years could further affect share count.
Background
Mangoceuticals filed an 8‑K reporting amendments to its preferred stock series and the creation of a new Series D class.
Ticker impact
SEC Form 8‑K discloses creation of senior Series D convertible preferred stock and amendments to Series B and C designations.
likely downside as investors price in senior liquidation preference and potential dividend obligations.
The filing introduces a higher‑ranking security that could reduce equity value and increase cash‑flow commitments.
Market effects
minimal impact on broader biotech sector; primarily a company‑specific capital structure change.
none
none
Counterpoint
If the Series D capital is used for growth initiatives, the dilution may be offset by future earnings.
Key entities
- companyMangoceuticals, Inc.
Biopharma company filing the preferred‑stock amendment.
